29 March, 2023 | Wednesday | News

Discovered and developed in-house by Antengene's R&D team, ATG-022 is an antibody-drug-conjugate (ADC) targeting the Tumor Associated Antigen (TAA) Claudin 18.2. The Phase I CLINCH trial&n...

31 March, 2023 | Friday | News

The system's Liquid Manager feature offers predefined pipette settings and technique hints for a variety of liquids, ensuring consistent and accurate results in several applications. Users can also define their...

31 March, 2023 | Friday | Company results

Revenue of the Group for the year ended December 31, 2022 was approximately US$625.7 million, representing an increase of 27.7% as compared with approximately US$490.1 million for the...

01 April, 2023 | Saturday | News

Very promising preclinical results of the apoA-I biovector in an acute inflammation model Development of safe corticoids to limit traditional corticoid-related side effects when used in AMD or DME Project t...

29 March, 2023 | Wednesday | News

The program will enable Verbal Beginnings' clients, families, and caregivers to remotely report on the health outcomes that matter most to them, including social communication, behavioral functioning, and quali...